查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046639

心房顫動市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型分類，2021-2031年

Atrial Fibrillation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment, By End-use, By Region & Competition), 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球心房顫動市場預計將經歷顯著成長，從 2025 年的 226.1 億美元成長到 2031 年的 353.4 億美元，複合年成長率達到 7.73%。

該市場涵蓋用於診斷、管理和治療心律不整的各種醫療設備和藥品，例如電生理消融導管、診斷標測系統和左心耳封堵器。主要成長要素包括老年人口的增加以及高血壓和肥胖等慢性疾病在全球範圍內的日益流行，這些疾病都會增加心律不整的風險。例如，預計到2025年，英國將新增162萬例心房顫動診斷病例，凸顯了日益成長的臨床需求。然而，限制市場擴張的主要因素是先進的電生理手術和持續疾病管理的高昂費用。這導致了嚴格的報銷政策和有限的患者就醫機會，尤其是在對成本敏感的醫療保健系統和新興市場。

市場概覽
預測期 2027-2031
市場規模：2025年 226.1億美元
市場規模：2031年 353.4億美元
複合年成長率：2026-2031年 7.73%
成長最快的細分市場 醫院
最大的市場 北美洲

市場促進因素

脈衝電場消融（PFA）系統的出現大大推動了這個市場的發展。 PFA是一種治療方法。它能夠在選擇性消融心肌組織的同時保護周圍組織，從而縮短手術時間，並迅速被電生理學家應用於各種房顫病例中。例如，波士頓科學公司的Farapulse PFA系統在上市第一年就實現了10億美元的銷售額，凸顯了這項技術的變革。此外，高血壓和肥胖等心血管合併症的日益普遍也顯著擴大了需要治療的患者群體。預計到2025年，美國將有約1.279億成年人患有某種形式的心血管疾病，因此對擴充性的心房顫動管理解決方案的需求正在不斷成長。預計這將推動製造商的強勁成長，強生公司循環系統部門在2025年第二季22.3%的成長就證明了這一點。

市場挑戰

全球心房顫動市場擴張的主要障礙在於先進電生理手術和持續疾病管理的高昂費用。諸如心導管電氣燒灼術和左心耳封堵術等手術需要對專用設備和基礎設施進行大量投資，導致醫療保險公司實施嚴格的報銷政策，限制了患者的就醫途徑。這種經濟障礙減緩了新醫療技術的普及，尤其是在對成本高度敏感的醫療體系和新興經濟體。慢性病治療的長期費用，包括終身抗凝血治療和持續監測，進一步加重了這項經濟負擔。據估計，到2025年，英國房顫的年度治療費用將超過24億英鎊，這項經濟負擔導致了限制性政策的訂定，並阻礙了市場的整體發展。

市場趨勢

兩大趨勢正在塑造心房顫動市場：左心耳封堵裝置的日益普及和新一代因子XIa抑制劑的研發。臨床醫師擴大採用左心耳封堵裝置作為預防中風的非藥物方法，尤其是在易發生出血併發症的高風險患者中，從而逐漸減少長期口服抗凝血治療。這種轉變促使製造商專注於研發更安全、更有效的裝置，並加速其市場推廣。波士頓科學公司的「Watchman」系列就是一個典型的例子，該系列在2025年第二季度實現了28.4%的成長。同時，新一代因子XIa抑制劑正成為製藥領域的變革性趨勢。這些新療法可望透過預防血栓形成來增強中風預防效果，同時又不損害人體自身的止血功能，從而顯著降低嚴重出血事件的發生率，而嚴重出血事件正是現有抗凝血劑的主要安全隱患。例如，因子 XI 抑制劑 avelacimab 已被證明與Rivaroxaban相比可減少 62% 的出血事件，這表明其具有顯著的臨床潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球心房顫動市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（藥物治療（抗心律不整藥物）、非藥物治療（心導管電氣燒灼術、迷宮手術、電擊去心房顫動））
    • 依用途（醫院、專科診所、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心房顫動市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲心房顫動市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區心房顫動市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲心房顫動市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲心房顫動市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球心房顫動市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Parexel International Corporation
  • AtriCure Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • Cardio Focus Inc.
  • Sanofi SA
  • Biosense Webster Inc.
  • Endoscopic Technologies Inc.
  • Abbott Laboratories
  • Johnsons & Johnson Services, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16271

The Global Atrial Fibrillation Market is poised for significant growth, projected to expand from USD 22.61 Billion in 2025 to USD 35.34 Billion by 2031, achieving a CAGR of 7.73%. This market encompasses various medical devices and pharmaceutical treatments for diagnosing, managing, and treating irregular cardiac rhythms, including electrophysiology ablation catheters, diagnostic mapping systems, and left atrial appendage closure devices. Key growth drivers include an expanding geriatric population and the increasing global prevalence of chronic conditions like hypertension and obesity, which elevate arrhythmia risk. For instance, in 2025, the UK recorded 1.62 million atrial fibrillation diagnoses, highlighting the growing clinical need. However, a major impediment to market expansion is the high cost of advanced electrophysiology procedures and ongoing disease management, leading to stringent reimbursement policies and restricted patient access, particularly in cost-sensitive healthcare systems and emerging markets.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 22.61 Billion
Market Size 2031USD 35.34 Billion
CAGR 2026-20317.73%
Fastest Growing SegmentHospital
Largest MarketNorth America

Market Driver

The market is significantly driven by the advent of Pulsed Field Ablation (PFA) systems, which offer a safer and more efficient non-thermal alternative to traditional ablation techniques. PFA's ability to selectively ablate myocardial tissue while protecting surrounding structures has led to reduced procedural times and rapid adoption by electrophysiologists for various atrial fibrillation cases. Boston Scientific's Farapulse PFA system, for example, generated $1 billion in revenue within its first year, demonstrating this technological shift. Furthermore, the rising prevalence of cardiovascular comorbidities, such as hypertension and obesity, greatly expands the patient population needing interventions. With approximately 127.9 million U.S. adults affected by some form of cardiovascular disease in 2025, the demand for scalable atrial fibrillation management solutions is intensifying, leading to strong growth for manufacturers, as evidenced by Johnson & Johnson's cardiology division's 22.3% growth in Q2 2025.

Market Challenge

A significant impediment to the Global Atrial Fibrillation Market's expansion is the considerable cost of advanced electrophysiology procedures and ongoing disease management. Procedures like catheter ablation and left atrial appendage closure demand substantial investment in specialized equipment and infrastructure, leading healthcare payers to impose strict reimbursement policies that limit patient access. This financial barrier often slows the adoption of new medical technologies, particularly in cost-sensitive healthcare systems and emerging economies. The economic strain is compounded by the long-term expenses of chronic care, including lifelong anticoagulation and continuous monitoring. With the annual cost of managing atrial fibrillation in the UK estimated to surpass £2.4 billion in 2025, this fiscal burden drives restrictive purchasing policies that hinder overall market development.

Market Trends

Two key trends are shaping the atrial fibrillation market: the growing utilization of Left Atrial Appendage Closure Devices and the development of Next-Generation Factor XIa Inhibitors. Clinicians are increasingly adopting Left Atrial Appendage Closure Devices for non-pharmacological stroke prevention, particularly for high-risk patients prone to bleeding complications, moving away from long-term oral anticoagulation. This shift has led manufacturers to innovate with safer, more effective devices, accelerating adoption, as seen in Boston Scientific's Watchman franchise, which grew by 28.4% in Q2 2025. Concurrently, Next-Generation Factor XIa Inhibitors are emerging as a transformative pharmaceutical trend. These novel therapeutics promise to enhance stroke prophylaxis by preventing clot formation without impairing natural hemostasis, thereby significantly reducing major bleeding events-a critical safety concern with existing anticoagulants. For instance, the Factor XI inhibitor abelacimab demonstrated a 62% reduction in bleeding events compared to rivaroxaban, indicating its substantial clinical potential.

Key Market Players

  • Parexel International Corporation
  • AtriCure Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol- Myers Squibb Corporation
  • Cardio Focus Inc.
  • Sanofi S.A.
  • Biosense Webster Inc.
  • Endoscopic Technologies Inc.
  • Abbott Laboratories
  • Johnsons & Johnson Services, Inc.

Report Scope

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type

  • Pharmacological Treatment
  • Non-Pharmacological Treatment

Atrial Fibrillation Market, By End-use

  • Hospital
  • Specialty Clinics
  • Others

Atrial Fibrillation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion))
    • 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Atrial Fibrillation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Atrial Fibrillation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Atrial Fibrillation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End-use

7. Europe Atrial Fibrillation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Atrial Fibrillation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Atrial Fibrillation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Atrial Fibrillation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Atrial Fibrillation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Atrial Fibrillation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End-use

8. Asia Pacific Atrial Fibrillation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Atrial Fibrillation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End-use
    • 8.3.2. India Atrial Fibrillation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End-use
    • 8.3.3. Japan Atrial Fibrillation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Atrial Fibrillation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Atrial Fibrillation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End-use

9. Middle East & Africa Atrial Fibrillation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Atrial Fibrillation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End-use
    • 9.3.2. UAE Atrial Fibrillation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End-use
    • 9.3.3. South Africa Atrial Fibrillation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End-use

10. South America Atrial Fibrillation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Atrial Fibrillation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End-use
    • 10.3.2. Colombia Atrial Fibrillation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End-use
    • 10.3.3. Argentina Atrial Fibrillation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Parexel International Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AtriCure Inc.
  • 15.3. Boehringer Ingelheim GmbH
  • 15.4. Boston Scientific Corporation
  • 15.5. Bristol- Myers Squibb Corporation
  • 15.6. Cardio Focus Inc.
  • 15.7. Sanofi S.A.
  • 15.8. Biosense Webster Inc.
  • 15.9. Endoscopic Technologies Inc.
  • 15.10. Abbott Laboratories
  • 15.11. Johnsons & Johnson Services, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer